Skip to main content
Thomas Schuetz, MD, Oncology, Framingham, MA

ThomasJosephSchuetzMD

Oncology • Framingham, MA

Physician

Join to view full profile

Are you Dr. Schuetz?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 22 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Thomas Schuetz, MD is an oncologist in Framingham, Massachusetts. He is currently licensed to practice medicine in Massachusetts.

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1995 - 1998
  • Harvard Medical School
    Harvard Medical SchoolClass of 1993

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1995 - 2019

Publications & Presentations

PubMed

Press Mentions

  • Compass Therapeutics Announces That the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) Will Be Presented at the ASCO GI Cancers Symposium on January 20, 2023
    Compass Therapeutics Announces That the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) Will Be Presented at the ASCO GI Cancers Symposium on January 20, 2023January 19th, 2023
  • Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor a (VEGF-A)
    Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor a (VEGF-A)January 20th, 2022
  • CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 8th, 2021
  • Join now to see all

Dr. Thomas Schuetz, Dr. Thomas Schuetz, MD, Dr. T Schuetz, Dr. Thomas Joseph Schuetz